Viz.ai, a company involved in AI-backed imaging and care coordination, is collaborating with pharma giant Novartis to develop proprietary AI-powered workflows inside the Viz Oncology Suite.
Viz.ai offers a care coordination platform featuring more than 50 FDA-cleared algorithms that help analyze medical imaging data to provide insights into diagnoses, ease workflows and support treatment decisions.Â
The companies will focus on improving the “identification and stratification of patients diagnosed with prostate and breast cancers based on crucial risk factors, accelerating access to guideline-based precision treatments.”
The collaboration also aims to address delays in diagnosis and treatment by utilizing AI to help ensure patients are identified and treated sooner with timely, coordinated care.
Viz.ai plans to develop two new AI-powered offerings: Viz Prostate Cancer, designed to identify eligible patients for guideline-based treatment with referrals to an applicable specialist, and Viz Breast Cancer, an offering that supports breast oncologists by automating patient reviews, aggregating risk-relevant data, introducing therapeutic guidelines and promoting coordination among multidisciplinary care teams.
“We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer,” Dr. Chris Mansi, CEO and cofounder of Viz.ai, said in a statement.Â
“This collaboration is part of our broader strategic expansion into oncology, furthering Viz.ai’s mission to fundamentally transform healthcare through intelligent care coordination.”
THE LARGER TREND
In May, Viz.ai partnered with Regeneron, a biotechnology company, and Sanofi, a biopharmaceutical company, to deploy and study an AI-enabled workflow tool for COPD.Â
Through the partnership, Sanofi and Regeneron will support Viz.ai’s investigation of its Viz COPD Module, which utilizes AI and electronic health record data to identify and manage high-risk COPD patients. Â
In 2023, Viz.ai signed a multi-year agreement with Bristol Myers Squibb to release an AI-enabled algorithm and software for provider workflow dubbed Viz HCM.Â
Viz HCM is used to help identify and assess patients for hypertrophic cardiomyopathy by reviewing routine electrocardiograms and identifying suspected cases for clinical review. It was integrated into Viz.ai’s Cardio Suite offering.Â
In 2023, Dawn Health entered into a strategic partnership with Novartis to develop a chronic condition management platform.Â
Under the collaboration, Dawn and Novartis built remote monitoring and management tools for chronic conditions where they see an unmet need and concerns around disease progression, such as multiple sclerosis, hypertension, cardiovascular disease and breast cancer.
The platform includes patient mobile apps, symptom monitoring, digital biomarkers, clinical decision support services and virtual clinic offerings tailored to specific diseases and conditions.Â
In 2022, Anumana, a joint venture between nference, an EHR data company, and the Mayo Clinic, entered a strategic partnership with Novartis to develop artificial intelligence tools for detecting cardiovascular diseases.
The collaboration focused on deploying AI algorithms that analyze ECGs to find left ventricular dysfunction, which can lead to heart failure and atherosclerotic cardiovascular disease.
Viz.ai, a company involved in AI-backed imaging and care coordination, is collaborating with pharma giant Novartis to develop proprietary AI-powered workflows inside the Viz Oncology Suite.
Viz.ai offers a care coordination platform featuring more than 50 FDA-cleared algorithms that help analyze medical imaging data to provide insights into diagnoses, ease workflows and support treatment decisions.Â
The companies will focus on improving the “identification and stratification of patients diagnosed with prostate and breast cancers based on crucial risk factors, accelerating access to guideline-based precision treatments.”
The collaboration also aims to address delays in diagnosis and treatment by utilizing AI to help ensure patients are identified and treated sooner with timely, coordinated care.
Viz.ai plans to develop two new AI-powered offerings: Viz Prostate Cancer, designed to identify eligible patients for guideline-based treatment with referrals to an applicable specialist, and Viz Breast Cancer, an offering that supports breast oncologists by automating patient reviews, aggregating risk-relevant data, introducing therapeutic guidelines and promoting coordination among multidisciplinary care teams.
“We are excited to be partnering with Novartis, an innovative medicines company and a leader in oncology, to accelerate access to timely, guideline-based care for patients facing prostate and breast cancer,” Dr. Chris Mansi, CEO and cofounder of Viz.ai, said in a statement.Â
“This collaboration is part of our broader strategic expansion into oncology, furthering Viz.ai’s mission to fundamentally transform healthcare through intelligent care coordination.”
THE LARGER TREND
In May, Viz.ai partnered with Regeneron, a biotechnology company, and Sanofi, a biopharmaceutical company, to deploy and study an AI-enabled workflow tool for COPD.Â
Through the partnership, Sanofi and Regeneron will support Viz.ai’s investigation of its Viz COPD Module, which utilizes AI and electronic health record data to identify and manage high-risk COPD patients. Â
In 2023, Viz.ai signed a multi-year agreement with Bristol Myers Squibb to release an AI-enabled algorithm and software for provider workflow dubbed Viz HCM.Â
Viz HCM is used to help identify and assess patients for hypertrophic cardiomyopathy by reviewing routine electrocardiograms and identifying suspected cases for clinical review. It was integrated into Viz.ai’s Cardio Suite offering.Â
In 2023, Dawn Health entered into a strategic partnership with Novartis to develop a chronic condition management platform.Â
Under the collaboration, Dawn and Novartis built remote monitoring and management tools for chronic conditions where they see an unmet need and concerns around disease progression, such as multiple sclerosis, hypertension, cardiovascular disease and breast cancer.
The platform includes patient mobile apps, symptom monitoring, digital biomarkers, clinical decision support services and virtual clinic offerings tailored to specific diseases and conditions.Â
In 2022, Anumana, a joint venture between nference, an EHR data company, and the Mayo Clinic, entered a strategic partnership with Novartis to develop artificial intelligence tools for detecting cardiovascular diseases.
The collaboration focused on deploying AI algorithms that analyze ECGs to find left ventricular dysfunction, which can lead to heart failure and atherosclerotic cardiovascular disease.
